Cargando…

Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease

BACKGROUND: High-profile Phase 3 clinical trials of bapineuzumab and solanezumab, antibodies targeted at amyloid-beta (Aβ) removal, have failed to meet their primary endpoints. Neither drug improves clinical outcomes in patients with late onset AD, joining a long list of unsuccessful attempts to tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Castello, Michael A, Jeppson, John David, Soriano, Salvador
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236650/
https://www.ncbi.nlm.nih.gov/pubmed/25179671
http://dx.doi.org/10.1186/s12883-014-0169-0

Ejemplares similares